The stakes of an unregulated supply chain
This isn't a reason for alarm, but it is a reason for diligence. Regulatory oversight of this category is still developing, and a researcher who waits for a third party to catch a quality problem is taking on unnecessary risk. A peptide that's mislabeled, degraded, or cut with an inactive filler is best caught by whoever receives the material and knows what to check for, not after the fact. That's the role a Certificate of Analysis is meant to play.
Research peptides occupy an unusual space. They're widely used in laboratory and academic research, yet the regulatory framework governing this category is narrower than the one that governs approved pharmaceuticals, and it continues to evolve. Facility inspection and label verification for peptide vendors don't carry the same built-in assurance a researcher gets from an FDA-regulated drug manufacturer. That gap is filled, imperfectly, by documentation, and understanding that documentation is the single most useful skill a researcher or lab can bring to sourcing decisions.
What a Certificate of Analysis actually verifies
A Certificate of Analysis, or COA, is a lab report generated after a sample of a specific production batch has been tested. A legitimate COA for a research peptide typically documents three things:
Identity. Confirmation that the compound present is, in fact, the compound claimed, not a structurally similar substitute, not a degraded fragment, not an entirely different material. This is usually established through methods like mass spectrometry, which can confirm a molecule's identity based on its mass and structure.
Purity. A quantitative measurement, most often via reversed-phase HPLC (high-performance liquid chromatography), expressing what percentage of the sample is the intended compound versus synthesis byproducts, degradation products, or residual reagents. Purity figures in the high 90s are standard for a well-synthesized research peptide; anything meaningfully lower warrants scrutiny.
Contaminant and residual solvent screening. Peptide synthesis involves chemical processes that can leave trace solvents or reagents behind if purification isn't done thoroughly. A rigorous COA screens for these residuals rather than assuming they're absent.
It's worth distinguishing a batch-specific COA from a generic one. A batch-specific COA reports results tied to a particular lot number: the specific material a lab is actually receiving. A generic COA, sometimes reused across multiple production runs or even presented as a "representative" result, tells you far less, because synthesis quality can vary meaningfully from batch to batch.
Why third-party testing is the credibility bar
A COA is only as credible as the lab that produced it. That's the clearest fault line in this market. Some vendors test their own products in-house and issue their own certificates. Others commission testing from an independent, accredited third-party laboratory with no financial stake in the result.
The difference matters because in-house testing creates an obvious conflict of interest: the entity selling the product is also the entity grading its own work, with no external check on accuracy. Third-party testing removes that conflict. An independent lab has no incentive to report a favorable purity figure or omit a contaminant; its business is testing accuracy, not peptide sales. For this reason, third-party verification is widely treated as the baseline for a credible COA, not an optional upgrade.
Reading a COA: what to look for
A real COA, read carefully, tells a researcher most of what they need to know before relying on a material for research. A few elements consistently separate a trustworthy document from a weak one:
- A named, identifiable testing lab. If the lab isn't named, or can't be independently verified to exist, the certificate's claims can't be checked against anything.
- A batch or lot number that matches the product in hand. A COA with no batch reference, or one that doesn't correspond to what's physically received, isn't verifying the thing being sold.
- A recent test date relative to the batch. Testing performed close to production and sale is more meaningful than a certificate issued long before the material shipped.
- A full contaminant panel, not purity alone. Purity percentage is necessary but not sufficient; a document that reports purity and nothing else is incomplete.
- Specific, quantitative results, not vague pass/fail language. "99.8% purity, identity confirmed via mass spectrometry" is verifiable. "Meets quality standards" is not.
Why this matters for the research itself
Every finding in the peptide research literature rests on an implicit assumption: that the compound actually used in the study was the compound the researchers believed they were using, at a known purity. Sourcing quality isn't separate from research validity. It's a precondition for it. A result obtained with a mislabeled or contaminated compound isn't really a result about that compound at all.
This is part of why documentation practices have become a point of differentiation among research-material suppliers. Questions that once seemed niche, such as who issued a COA, what it actually tested, and how recently, have become reasonable baseline expectations for any lab or institution sourcing research peptides.
Research use only. Material supplied under this category is manufactured and tested to a research-grade specification. It is not evaluated by the FDA and is not labeled, tested, or intended for human or veterinary use.
See how Force Peptides documents this for every batch: Certificates of Analysis